Publications

Publications

 

  1. 1. Gal-Tanamy M, Magal N, Halpern GJ, Jaber L, Shohat M. Fine mapping places the gene for arthrogryposis multiplex congenita neuropathic type between D5S394 and D5S2069 on chromosome 5qter. Am J Med Genet. 2001 Nov 22; 104(2):152-6.
  2. Gargir A, Ofek I, Meron Sudai S, Gal-Tanamy M, Kabouridis PS, Nissim A. Single chain antibodies specific for fatty acids derived from a semi-synthetic phage display library. Biochim Biophys Acta. 2002 Jan 15; 1569(1-3): 167-73.
    3. Gal-Tanamy M, Zemel R, Berdichevsky Y, Bachmatov L, Tur-Kaspa R , Benhar I. HCV NS3 serine protease neutralizing single-chain antibodies isolated by a novel genetic screen. J Mol Biol. 2005 Apr 15;347(5):991-1003.
    4. Trahtenherts A, Gal-Tanamy M, Zemel R, Bachmatov L, Loewenstein S, Tur-Kaspa R, Benhar I. Inhibition of hepatitis C virus RNA replicons by peptide aptamers. Antiviral Res. 2008 Mar;77(3):195-205.
    5. Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset FL, Lemon SM, Foung SK. A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol. 2008 Jun;82(12):6067-72. (PDF)
    6. Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.J Virol. 2008 Jun;82(12):6061-6. (PDF)
    7. Gal-Tanamy M, Keck ZY, Yi M, McKeating JA, Patel AH, Steven K.H. Foung, and Stanley M. Lemon. In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19450-5. (PDF)
    8. Gal-Tanamy M, Walker C, Foung SK, Lemon SM. Vaccines for Hepatitis C Virus. In: Vaccines for Biodefense and Emerging and Neglected Diseases. Academic Press, 2009:413-440.
    9. Gal-Tanamy M, Zemel R, Bachmatov L, Jangra RK, Villanueva RA, Yi M, Lemon SM, Benhar I, Tur-Kaspa R. Inhibition of HCV drug resistant replicons and cell culture infectious virus by intrabodies. Antiviral Res. 2010 Oct ;88(1):95-106
    10. Shapira A, Gal-Tanamy M, Nahary L, Litvak-Greenfeld D, Zemel R, Tur-Kaspa R, Benhar I. “Zimoxins”, engineered toxins that are activated by the HCV NS3 protease through removal of an inhibitory protein domain selectively kill HCV infected cells. PLoS One. 2011 Jan 14;6(1):e15916 (PDF)
    11. Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, Zemel R. Vitamin-D: an innate antiviral agent suppressing Hepatitis C virus in human hepatocytes. Hepatology. 2011 Nov;54(5):1570-9.
    12. Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat. 2012 Feb;19(2):e81-8.
    13. Shapira A, Shapira S, Gal-Tanamy M, Zemel R, Tur-Kaspa R, Benhar I. Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin. PLoS One. 2012 Feb 16;7(2):e32320. (PDF)
    14. Eliyahu S, Sharabi O, Elmedvi S, Timor R, Davidovich A, Vigneault F, Clouser C, Hope R, Nimer A, Braun M, Weiss YY, Polak P, Yaari G, Gal-Tanamy M.Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance. Front Immunol. 2018 Dec 21;9:3004. doi: 10.3389/fimmu.2018.03004. eCollection 2018. (PDF)
    15. Perez S, Gal-Tanamy M. Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals.
    Methods Mol Biol. 2019;1911:191-207. doi: 10.1007/978-1-4939-8976-8_13. (PDF)
    16. Gal-Tanamy M. Multi-omic Analyses Reveal Complex Interactions Between HCV and Hepatocytes Demonstrating That the Red Queen Is Up and Running.
    17. Gastroenterology. 2019 Aug;157(2):300-302. doi: 10.1053/j.gastro.2019.06.005. Epub 2019 Jun 13.(PDF)
    18. Ninio L, Nissani A, Meirson T, Domovitz T, Genna A, Twafra S, Srikanth KD, Dabour R, Avraham E, Davidovich A, Gil-Henn H, Gal-Tanamy M. Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation. Cells. 2019 Nov 5;8(11):1395. doi: 10.3390/cells8111395.
    19. Perez S, Gevor M, Davidovich A, Kaspi A, Yamin K, Domovich T, Meirson T, Matityahu A, Brody Y, Stemmer SM, El-Osta A, Haviv I, Onn I, Gal-Tanamy M. Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates host-virus interactions. Nucleic Acids Res. 2019 Mar 18;47(5):2455-2471. doi: 10.1093/nar/gkz052.
    20. Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, Nimer A, El-Osta A, Yaari G, Stemmer SM, Yu ML, Haviv I, Gal-Tanamy M. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019 Jun 19;15(6):e1008181. doi: 10.1371/journal.pgen.1008181. eCollection 2019 Jun.
    21. Zucker I, Lester Y, Alter J, Werbner M, Yecheskel Y, Gal-Tanamy M, Dessau M. Pseudoviruses for the assessment of coronavirus disinfection by ozone. Environ Chem Lett. 2021 Jan 13:1-7. doi: 10.1007/s10311-020-01160-0.
    22. Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med. 2021 Feb 2;10(3):551. doi: 10.3390/jcm10030551.(PDF)
    23. Mor M, Werbner M, Alter J, Safra M, Chomsky E, Lee JC, Hada-Neeman S, Polonsky K, Nowell CJ, Clark AE, Roitburd-Berman A, Ben-Shalom N, Navon M, Rafael D, Sharim H, Kiner E, Griffis ER, Gershoni JM, Kobiler O, Leibel SL, Zimhony O, Carlin AF, Yaari G, Dessau M, Gal-Tanamy M, Hagin D, Croker BA, Freund NT. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. PLoS Pathog. 2021 Feb 11;17(2):e1009165. doi: 10.1371/journal.ppat.1009165. eCollection 2021 Feb.(PDF)
    24. Domovitz T, Ayoub S, Werbner M, Alter J, Izhaki-Tavor L, Yahalom-Ronen Y, Tikhonov E, Meirson T, Maman Y, Paran N, Israely T, Dessau M, Gal-Tanamy M. HCV Infection Increases the Expression of ACE2 Receptor, Leading to Enhanced Entry of Both HCV and SARS-CoV-2 into Hepatocytes and a Coinfection State. Microbiol Spectr. 2022 Oct 31:e0115022. doi: 10.1128/spectrum.01150-22.(PDF)
    25. Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group (RECOVER). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology. 2022 Feb;162(2):454-467. doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587(PDF).
    26. Rosenberg-Friedman M, Kigel A, Bahar Y, Werbner M, Alter J, Yogev Y, Dror Y, Lubetzky R, Dessau M, Gal-Tanamy M, Many A, Wine Y. BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women. Nat Commun. 2021 Oct 28;12(1):6222. doi: 10.1038/s41467-021-26507-1. PMID: 34711825; PMCID: PMC8553805.(PDF)
    27. Samuels H, Malov M, Saha Detroja T, Ben Zaken K, Bloch N, Gal-Tanamy M, Avni O, Polis B, Samson AO. Autoimmune Disease Classification Based on PubMed Text Mining. J Clin Med. 2022 Jul 26;11(15):4345. doi: 10.3390/jcm11154345. PMID: 35893435; PMCID: PMC9369164(PDF)
    28. Yamin K, Bijlani S, Berman J, Soni A, Shlomai J, Buragohain BM, Werbner M, Gal-Tanamy M, Matityahu A, Onn I. Fold-change of chromatin condensation in yeast is a conserved property. Sci Rep. 2022 Oct 17;12(1):17393. doi: 10.1038/s41598-022-22340-8. PMID: 36253460; PMCID: PMC9576780.(PDF)